MedTrace Logo

A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

NCT04172233 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2025-03-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and the preliminary efficacy of AK101，an anti-IL-12/23p40 monoclonal antibody, when administered subcutaneously in subjects with moderate-to-severe plaque psoriasis.

Conditions

Interventions

BIOLOGICAL

AK101

AK101 is an anti-IL-12/23p40 monoclonal antibody.

BIOLOGICAL

placebo

matching placebo

Sponsors & Collaborators

  • Akeso Tiancheng, Inc

    collaborator OTHER

  • Akeso

    lead INDUSTRY

Principal Investigators

  • Rui Chen, MD · Peking Union Medical College Hospital

  • Hongzhong Jin, MD · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-09
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04172233 on ClinicalTrials.gov